BioSpace News Archive

Ensysce Biosciences, Inc. today announced that its management has been invited to present at the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York, NY on September 11-13, 2023.

Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview and participate in one-on-one meetings at the Baird Global Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference, both being held in New York, NY.

Travere Therapeutics, Inc. and Mirum Pharmaceuticals, Inc. announced the completion of the previously announced sale of Travere’s bile acid product portfolio that includes Cholbam® and Chenodal®, two medications addressing rare diseases in high-need settings.

Avenue Therapeutics, Inc. today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference scheduled to take place September 11-13, 2023.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, from 12:00-12:30pm ET.

Carisma Therapeutics Inc. today announced that it will present at several upcoming investor conferences.

Moleculin Biotech, Inc. today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will present new preclinical data from a study of povetacicept in a murine experimental autoimmune myasthenia gravis (EAMG) model during the 148th Annual American Neurological Association (ANA) Meeting in Philadelphia, PA.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).

IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023 at 10:50 a.m. ET.